Literature DB >> 26162687

Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.

Lauryn R Werner1, Shyhmin Huang1, David M Francis1, Eric A Armstrong1, Fang Ma1, Chunrong Li1, Gopal Iyer1, Jude Canon2, Paul M Harari3.   

Abstract

MDM2-p53 interaction and downstream signaling affect cellular response to DNA damage. AMG 232 is a potent small molecule inhibitor that blocks the interaction of MDM2 and p53. We examined the capacity of AMG 232 to augment radiation response across a spectrum of human tumor cell lines and xenografts. AMG 232 effectively inhibited proliferation and enhanced radiosensitivity via inhibition of damage repair signaling. Combined AMG 232 and radiation treatment resulted in the accumulation of γH2AX-related DNA damage and induction of senescence with promotion of apoptotic and/or autophagic cell death. Several molecules involved in senescence, autophagy, and apoptosis were specifically modulated following the combined AMG 232/radiation treatment, including FoxM1, ULK-1, DRAM, and BAX. In vivo xenograft studies confirmed more potent antitumor and antiangiogenesis efficacy with combined AMG 232/radiation treatment than treatment with drug or radiation alone. Taken together, these data identify the capacity of AMG 232 to augment radiation response across a variety of tumor types harboring functional p53. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26162687     DOI: 10.1158/1535-7163.MCT-14-1056-T

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  19 in total

1.  Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.

Authors:  Maite Verreault; Charlotte Schmitt; Lauriane Goldwirt; Kristine Pelton; Samer Haidar; Camille Levasseur; Jeremy Guehennec; David Knoff; Marianne Labussière; Yannick Marie; Azra H Ligon; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Brian M Alexander; Patrick Y Wen; Jean-Yves Delattre; Keith L Ligon; Ahmed Idbaih
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

2.  Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition.

Authors:  Prashanth J Prabakaran; Amal M Javaid; Adam D Swick; Lauryn R Werner; Kwangok P Nickel; Emmanuel Sampene; Rong Hu; Irene M Ong; Justine Y Bruce; Gregory K Hartig; Aaron M Wieland; Jude Canon; Paul M Harari; Randall J Kimple
Journal:  Clin Cancer Res       Date:  2017-06-28       Impact factor: 12.531

3.  Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas.

Authors:  Felipe Nör; Kristy A Warner; Zhaocheng Zhang; Gerson A Acasigua; Alexander T Pearson; Samuel A Kerk; Joseph I Helman; Manoel Sant'Ana Filho; Shaomeng Wang; Jacques E Nör
Journal:  Clin Cancer Res       Date:  2016-08-22       Impact factor: 12.531

4.  AMG-232, a New Inhibitor of MDM-2, Enhance Doxorubicin Efficiency in Pre-B Acute Lymphoblastic Leukemia Cells.

Authors:  Abbas Ghotaslou; Amir Samii; Hassan Boustani; Omid Kiani Ghalesardi; Minoo Shahidi
Journal:  Rep Biochem Mol Biol       Date:  2022-04

Review 5.  Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.

Authors:  Charles A Kunos; Evanthia Galanis; Jeffrey Buchsbaum; Qian Shi; Lewis C Strauss; C Norman Coleman; Mansoor M Ahmed
Journal:  J Neurooncol       Date:  2017-05-30       Impact factor: 4.130

6.  Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma.

Authors:  Lauryn R Werner; Jasdeep S Kler; Monica M Gressett; Maureen Riegert; Lindsey K Werner; Clinton M Heinze; Joseph G Kern; Mahyar Abbariki; Amy K Erbe; Ravi B Patel; Raghava N Sriramaneni; Paul M Harari; Zachary S Morris
Journal:  Radiother Oncol       Date:  2017-09-08       Impact factor: 6.280

7.  Screening and Validation of Molecular Targeted Radiosensitizers.

Authors:  Henning Willers; Xiao Pan; Nathalie Borgeaud; Irina Korovina; Lydia Koi; Regina Egan; Patricia Greninger; Aliza Rosenkranz; Jong Kung; Andrew S Liss; Leslie A Parsels; Meredith A Morgan; Theodore S Lawrence; Steven H Lin; Theodore S Hong; Beow Y Yeap; Lori J Wirth; Aaron N Hata; Christopher J Ott; Cyril H Benes; Michael Baumann; Mechthild Krause
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-07-31       Impact factor: 7.038

Review 8.  MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy.

Authors:  Xanthene Miles; Charlot Vandevoorde; Alistair Hunter; Julie Bolcaen
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

9.  Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.

Authors:  Rebecca L Shattuck-Brandt; Sheau-Chiann Chen; Emily Murray; Christopher Andrew Johnson; Holly Crandall; Jamye F O'Neal; Rami Nayef Al-Rohil; Caroline A Nebhan; Vijaya Bharti; Kimberly B Dahlman; Gregory D Ayers; Chi Yan; Mark C Kelley; Rondi M Kauffmann; Mary Hooks; Ana Grau; Douglas B Johnson; Anna E Vilgelm; Ann Richmond
Journal:  Clin Cancer Res       Date:  2020-03-31       Impact factor: 13.801

Review 10.  FOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathways.

Authors:  Fergal C Kelleher; Hazel O'Sullivan
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.